Progeria is a rare genetic disorder that causes premature aging in children. This condition usually begins to be seen in the first two years of life. Babies with progeria generally appear normal at birth, but then experience stunted growth and physical changes that resemble premature aging.

What Causes Progeria?

Progeria is caused by a mutation in the LMNA gene, which is a gene that functions to produce the lamin A protein that maintains the structure of the cell nucleus. This mutation causes the formation of an abnormal protein called progerin, which makes the cell unstable and breaks down quickly, triggering premature aging. Mutations in these genes usually occur spontaneously and are not passed down from parents. As a result of this mutation, there is progressive cell damage throughout the body which leads to the acceleration of the aging process and various serious health complications.

What are the types?

Progeria has several types based on the age of the onset of symptoms. The most common type is Hutchinson-Gilford Progeria Syndrome (HGPS) which occurs in children and toddlers.

In addition, there are several other types such as Werner Syndrome, which appears in adolescence or adulthood, and Cockayne Syndrome, which is also characterized by growth and nerve disorders. These three types have different genetic causes but are equally related to the accelerated aging process

Symptoms of Progeria

Symptoms of progeria are generally seen at the age of 1–2 years and include:

- Stunted growth and low body weight.

- Loss of subcutaneous fat and hair (alopesia).

- Thin and wrinkled skin.

- Small face, small jaw (micrognatia), and pointed nose.

- Clearly visible blood vessels under the skin.

- Joint stiffness and bone problems (e.g. early osteoporosis).

- The most serious complication is cardiovascular disease (heart disease and stroke), which is the leading cause of death in sufferers. Intellectual development in children with progeria is usually normal.

Handling

To date, there is no cure for progeria completely. Treatment is focused on reducing symptoms and prolonging the patient's life expectancy. Frequently used approaches include:

- Drug therapy: Lonafarnib (farnesiltransferase inhibitor) has shown benefits in extending life expectancy and reducing some complications in HGPS.

- Routine cardiovascular monitoring: cardiac examination, blood pressure, and lipid profiles.

- Symptomatic treatment: medication to manage blood pressure or cholesterol when needed.

- Supportive therapy: physiotherapy to maintain mobility, good nutrition to support growth, and orthopedic interventions when needed.

- Genetic counseling for families, although most cases appear sporadically.

Progeria is a rare disease due to a genetic mutation that causes accelerated aging in children. Although there is no complete cure, early detection, multidisciplinary treatment, and certain treatments such as lonafarnib can help improve the patient's life expectancy and quality of life.

References: